Cerebral BBB and Consumer-Complaint Trends: What the Data Actually Show

Is Cerebral a Legitimate Company?

Cerebral is a registered, operating telehealth company incorporated in Delaware and headquartered in San Francisco. It holds state telehealth licenses across the U.S. And accepts major insurance plans. Legitimacy in the legal sense, meaning the company exists, contracts with real licensed clinicians, and bills real insurers, is not genuinely in dispute. What is disputed, and what triggered federal and state inquiries, is whether the company's prescribing culture met acceptable clinical standards, particularly for Schedule II and III controlled substances like amphetamine salts and benzodiazepines.

Legal Standing vs. Clinical Quality

A company can be legally incorporated and operationally active while still generating harmful clinical outcomes. These are separate questions. The DEA's 2022 subpoena, reported by The Wall Street Journal and confirmed in subsequent coverage, focused specifically on whether Cerebral's prescribing practices for stimulants complied with the Controlled Substances Act. The DEA's Office of Diversion Control sets the federal floor for telemedicine prescribing of controlled substances, and those rules tightened again under the 2023 DEA telemedicine proposed rules following the expiration of COVID-19 telehealth flexibilities.

LegitScript Certification

LegitScript, a third-party healthcare compliance certification body, reviews online healthcare providers against pharmacy and prescribing standards. As of mid-2025, Cerebral does not appear on LegitScript's certified telehealth provider list. LegitScript certification is voluntary, but its absence means independent third-party verification of Cerebral's prescribing practices has not been publicly confirmed. Patients can check current certification status directly at LegitScript.com.

What Changed After 2022

Cerebral publicly stated in mid-2022 that it would stop prescribing stimulant medications for ADHD through its platform, citing regulatory concerns. The company later walked back a complete ban but reduced its controlled-substance prescribing footprint. These shifts directly affected patients mid-treatment, a pattern reflected in the consumer complaint data discussed below.

BBB Rating and Complaint Volume

The Better Business Bureau (BBB) profile for Cerebral Inc. Shows a pattern that differs from most telehealth competitors of similar scale. The BBB is not a government agency, and its ratings reflect complaint volume and response rate rather than clinical safety. Still, the raw complaint data is a useful early signal. The BBB's profile for Cerebral has logged hundreds of complaints since 2021, with billing, cancellation, and subscription issues consistently ranking as the top complaint categories.

Complaint Categories

Billing disputes make up the largest share of Cerebral's BBB complaints. Patients report being charged after cancellation, difficulty reaching customer service, and confusion about what their subscription actually covers versus what insurance pays. A second cluster involves prescription access: patients report prescriptions not being sent to pharmacies on time, clinician no-shows for scheduled appointments, and abrupt discontinuation of controlled-substance prescriptions without a taper plan.

The FDA's MedWatch program (https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) accepts adverse event reports for medication-related harms, including those arising from telehealth prescribing errors. Patients who experienced harm from abrupt prescription discontinuation may have grounds to file a report there independent of any BBB complaint.

Response Rate and Resolution

BBB complaints require company responses, and Cerebral has responded to the majority of filed complaints. Response is not the same as resolution. BBB records show a significant proportion of complaints closed without the customer considering the matter resolved. This pattern is relevant: a company can technically "respond" to every complaint while the underlying operational problem remains unaddressed.

How Cerebral's BBB Profile Compares

Direct competitors such as Talkspace and BetterHelp also carry BBB complaints, largely in the same billing and access categories. Cerebral's complaint density relative to its reported patient count has been higher than BetterHelp's during comparable periods, though direct per-patient comparisons require data Cerebral has not made public.

The DEA Investigation and Federal Scrutiny

Federal scrutiny of Cerebral's prescribing practices represents the most serious regulatory concern in its public record. In 2022, the DEA issued a subpoena to Cerebral related to its prescribing of controlled substances, specifically stimulant medications used to treat ADHD. This subpoena was widely reported, including by the Wall Street Journal and Reuters, and Cerebral confirmed it in a public statement.

Background on Telehealth Stimulant Prescribing Rules

During the COVID-19 public health emergency, the DEA permitted telemedicine prescribing of Schedule II controlled substances without an in-person evaluation under a temporary waiver. Cerebral's rapid growth in ADHD prescribing occurred largely within that window. When the emergency ended, the DEA proposed new rules governing telemedicine prescribing of controlled substances. The DEA's 2023 proposed rules would have required at least one in-person visit before a clinician could prescribe Schedule II stimulants via telemedicine. The rules generated significant public comment and were ultimately modified.

Cerebral's Internal Prescribing Culture

A former Cerebral employee told Reuters in 2022 that clinicians faced pressure to prescribe, with internal metrics that tracked prescription rates. Cerebral denied these characterizations. The DEA Diversion Control Division has authority to revoke DEA registrations of practitioners and, by extension, to affect the licenses under which a telehealth platform operates. No public record of a final DEA enforcement action specifically against Cerebral as a corporate entity had been published as of mid-2025, though the investigation remained a documented part of the company's regulatory history.

What the Ryan Haight Act Requires

The Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. 829) generally requires at least one in-person medical evaluation before a practitioner may issue a prescription for a controlled substance via the internet. Telehealth waivers during COVID-19 created exceptions to this requirement. As those waivers expire or are modified, any telehealth platform that built its patient base during the waiver period faces genuine compliance risk in maintaining those patients on controlled substances. Cerebral is not unique in this exposure, but its scale made it a particularly visible target.

State Medical Board and Attorney General Actions

State medical boards license the individual clinicians who prescribe through Cerebral's platform. The company itself does not hold a medical license, its clinicians do. This structure means state-level discipline typically targets the individual prescriber rather than the platform, which limits the visibility of state-level enforcement against Cerebral as a brand.

California

California's Medical Board (https://www.mbc.ca.gov/) has published disciplinary actions against individual physicians across telehealth contexts. Cerebral's California operations came under scrutiny following press coverage of its prescribing practices in 2022. Patients in California can search the Medical Board's license lookup tool to verify the current standing of any clinician assigned to them through Cerebral.

Multistate Telehealth Licensing

Cerebral's clinicians operate under either individual state licenses or, where available, the Interstate Medical Licensure Compact (IMLC). Patients should confirm their assigned clinician holds a valid license in their specific state of residence. A clinician licensed only in a different state cannot legally prescribe to a patient in most circumstances.

The table below outlines the three-question framework HealthRX recommends patients use before starting any controlled-substance prescription through a telehealth platform:

| Question | Where to Check | Red Flag | |---|---|---| | Does my assigned clinician hold a current, unrestricted license in my state? | State medical board license lookup | Expired, suspended, or out-of-state-only license | | Is this platform certified by LegitScript or a comparable third-party body? | LegitScript.com | No certification listed | | Has the platform or its affiliated prescribers received DEA, state board, or FTC action in the last 36 months? | DEA Diversion, state board, FTC.gov | Any unresolved or recent enforcement action |

Billing Complaints: The Consumer Protection Angle

Billing problems make up a disproportionate share of Cerebral's consumer complaint record. The Federal Trade Commission (FTC) enforces rules against unfair or deceptive billing practices under 15 U.S.C. 45. Subscription telehealth services that charge recurring fees and make cancellation difficult are squarely within the FTC's enforcement focus, particularly following the 2024 "click-to-cancel" rule (FTC Rule, 16 CFR Part 425).

What Patients Report

The most common billing complaint pattern in Cerebral's BBB file involves three steps: patient cancels subscription through the app or website, receives a confirmation, and is then charged again in the following billing cycle. When the patient contacts customer service, resolution reportedly takes multiple contacts and sometimes weeks.

A second pattern involves insurance billing errors. Patients report Cerebral billing their insurance for services that were not delivered, typically appointments the clinician did not attend or prescriptions that were never sent. Patients can verify claims against their insurance Explanation of Benefits (EOB) statements and report discrepancies to their state insurance commissioner.

Filing a Complaint

Patients with unresolved billing disputes have three primary escalation paths. First, file with the BBB. Second, file a complaint with the FTC at ReportFraud.ftc.gov. Third, file with the state attorney general's consumer protection division. All three generate a paper trail that can support a chargeback claim if the patient paid by credit card.

Mental Health Outcomes and Clinical Continuity

Mental health treatment is not analogous to treating a discrete acute condition. Interruptions to psychiatric medication, particularly antidepressants, mood stabilizers, and stimulants, carry real clinical risk. The FDA's labeling for selective serotonin reuptake inhibitors (SSRIs) warns against abrupt discontinuation due to the risk of discontinuation syndrome. Abrupt cessation of stimulants does not carry the same discontinuation risk but does affect functional outcomes in patients with ADHD.

Discontinuation Risk in Telehealth Contexts

A 2021 analysis published in JAMA Psychiatry examined treatment continuity in telehealth mental health settings and found that patient attrition and clinician turnover were both higher in app-based platforms than in traditional outpatient psychiatry. Higher clinician turnover increases the probability that a patient's prescribing clinician leaves the platform mid-treatment, which is exactly the pattern reported in Cerebral BBB complaints.

What the Research Shows on Telehealth Access

Telehealth does expand access to mental health care for patients who face geographic or financial barriers to in-person treatment. A 2020 study in Psychiatric Services found that telehealth delivery of cognitive behavioral therapy produced non-inferior outcomes to in-person delivery across a 12-week course for mild-to-moderate depression. The problem with Cerebral is not the telehealth modality. The problem, as documented in the complaint record, is operational execution and prescribing oversight.

ADHD Diagnosis Quality

The gold-standard evaluation for ADHD in adults involves structured clinical interviews, validated rating scales such as the Adult ADHD Self-Report Scale (ASRS), and collateral history. The American Academy of Child and Adolescent Psychiatry's practice parameter for ADHD recommends comprehensive evaluation before initiating stimulant treatment. Concerns raised in the DEA investigation centered on whether Cerebral's evaluation process was sufficiently thorough given the volume and speed of its ADHD diagnoses.

How Cerebral Compares to Other Telehealth Mental Health Platforms

Cerebral is not the only telehealth mental health company to face regulatory or consumer complaint pressure. BetterHelp settled a $7.8 million FTC action in 2023 for sharing user health data with Facebook and Snapchat without consent (FTC Press Release, March 2023). Talkspace has faced its own BBB complaints and class-action litigation over billing. The broader point is that consumer-facing telehealth mental health platforms as a category have an uneven track record on both clinical quality and consumer protection.

Choosing Between Platforms

Patients choosing between platforms should weight three factors differently depending on their needs. For therapy only (no medications), billing transparency and therapist credentialing matter most. For medication management, DEA compliance history and clinician turnover rate matter more. For ADHD specifically, the quality of the diagnostic evaluation process is a critical differentiator that platforms rarely disclose proactively.

The National Alliance on Mental Illness (NAMI) helpline can help patients identify vetted local and telehealth mental health resources as an alternative to navigating platform marketing materials.

Patient Safety Considerations

The clinical risks associated with Cerebral's documented operational problems are not hypothetical. Abrupt discontinuation of antidepressants can trigger discontinuation syndrome, characterized by dizziness, nausea, sensory disturbances, and rebound anxiety. The FDA's guidance on SSRI discontinuation recommends gradual dose reduction over weeks to months when stopping treatment. Patients whose access to prescriptions was interrupted by Cerebral's 2022 stimulant prescribing changes may not have received that taper guidance.

What to Do If Your Prescription Was Interrupted

If a Cerebral clinician stopped prescribing your medication without a transition plan, contact your primary care physician or a local psychiatrist immediately. Do not abruptly stop SSRIs, SNRIs, or benzodiazepines without medical supervision. For stimulant medications, abrupt discontinuation is generally safe but should still be managed with clinical support for symptom monitoring. The Substance Abuse and Mental Health Services Administration (SAMHSA) helpline at 1-800-662-4357 is available 24/7 for patients in mental health crisis.

Reporting Adverse Events

Patients who experienced clinical harm, not just billing frustration, from Cerebral's prescribing practices can file a MedWatch report with the FDA at https://www.fda.gov/safety/medwatch. Reports of clinician misconduct should go to the state medical board in the state where the prescribing clinician is licensed, not to Cerebral itself.

Current Status: What Has Changed Since 2022

Cerebral underwent significant leadership changes between 2022 and 2024. Founder Kyle Robertson stepped down as CEO in 2022. The company reduced its workforce in multiple rounds of layoffs. Its valuation, once reported at approximately $4.8 billion, dropped sharply as investor confidence declined following the regulatory news cycle.

Operational Changes

Cerebral publicly updated its clinical protocols following the 2022 scrutiny. The company stated it implemented additional safeguards for controlled-substance prescribing, including expanded clinician oversight and revised diagnostic evaluation requirements. These internal policy changes are difficult to verify independently because Cerebral has not published its clinical protocols in a form reviewable by outside researchers or clinicians.

Ongoing Concerns

As of mid-2025, BBB complaints continue to be filed against Cerebral, with billing and access issues persisting as the dominant categories. The DEA investigation status has not been resolved in a final published enforcement action available to the public. The absence of a published final action does not mean the matter closed favorably for Cerebral, DEA investigations can continue for years before resulting in published outcomes, or can be resolved through non-public consent agreements.

Patients considering Cerebral today should check the BBB's current complaint file and run their assigned clinician's name through their state medical board's public license lookup before their first appointment. A clinician whose license is current, unrestricted, and issued in the patient's state of residence is the minimum baseline for safe prescribing regardless of what platform delivers the appointment.